- Home
- OPCH vs TVTX Comparison
OPCH vs TVTX Comparison
Compare OPCH & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPCH | TVTX |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.8B |
| IPO Year | 1996 | 2013 |
Fundamental Metrics
Financial Performance| Metric | OPCH | TVTX |
|---|---|---|
| Price | $19.56 | $42.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $36.57 | ★ $40.62 |
| AVG Volume (30 Days) | ★ 3.5M | 2.7M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.25 | ★ 92.89 |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $4,998,202,000.00 | N/A |
| Revenue This Year | $7.21 | $44.76 |
| Revenue Next Year | $8.55 | $35.51 |
| P/E Ratio | $68.66 | ★ N/A |
| Revenue Growth | ★ 16.17 | N/A |
| 52 Week Low | $18.01 | $13.88 |
| 52 Week High | $36.80 | $48.61 |
Technical Indicators
Market Signals| Indicator | OPCH | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 21.62 | 62.11 |
| Support Level | $18.01 | $26.97 |
| Resistance Level | $29.13 | $48.61 |
| Average True Range (ATR) | 0.97 | 2.21 |
| MACD | -0.50 | -0.28 |
| Stochastic Oscillator | 13.27 | 36.23 |
Price Performance
Historical ComparisonAbout OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders, among others. The Company operates in one segment, infusion services.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.